Last reviewed · How we verify

NCT03706001

Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression

Status unknown NA Last updated 15 October 2018
What this trial tests

NA trial testing Psychotherapy in Hypertrophic Cardiomyopathy in 100 participants. Status unknown.

Timeline
20 October 2018
Primary endpoint
20 September 2019
31 December 2019

Quick facts

Lead sponsorXijing Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date20 October 2018
Primary completion20 September 2019
Estimated completion31 December 2019

Drugs / interventions tested

Conditions studied

Sponsor

Xijing Hospital

Who can join

18 and older, any sex, with Hypertrophic Cardiomyopathy or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Study to evaluate the efficacy of psychotherapy for easing the cardiac symptoms and improving and quality of life in patients with hypertrophic cardiomyopathy accompanied with depression

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Psychotherapy

Trials testing the same drug.

Other recruiting trials for Hypertrophic Cardiomyopathy

Currently open trials in the same condition.

Other Xijing Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03706001.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing